Energy balance, host-related factors, and cancer progression

Journal of Clinical Oncology

Volumn 28, Issue 26, 2010, Pages 4058-4065

  Hursting, Stephen D ^a   Berger, Nathan A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANDROGEN; CORTICOSTEROID; ESTROGEN; INSULIN; LEPTIN; PROGESTERONE; REACTIVE OXYGEN METABOLITE; SIRTUIN; SOMATOMEDIN C; STEROID HORMONE; SEX HORMONE; SIRT1 PROTEIN, HUMAN; SIRTUIN 1;

CANCER GROWTH; CANCER RISK; DISEASE ASSOCIATION; ENERGY BALANCE; HUMAN; INFLAMMATION; METABOLIC SYNDROME X; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; DISEASE COURSE; ENERGY METABOLISM; METABOLISM; NEOPLASM; PHYSIOLOGY;

ADIPONECTIN; ADRENAL CORTEX HORMONES; DISEASE PROGRESSION; ENERGY METABOLISM; GONADAL STEROID HORMONES; HUMANS; INFLAMMATION; INSULIN; INSULIN-LIKE GROWTH FACTOR I; LEPTIN; METABOLIC SYNDROME X; NEOPLASMS; OXIDATIVE STRESS; SIRTUIN 1;

EID: 77956917907     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.27.9935     Document Type: Review

References (140)

1. Calle E, Rodriguez C, Walker-Thurmond K, et al: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625-1638, 2003 (Pubitemid 36459468)
2. World Cancer Research Fund, American Institute for Cancer Research: Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. http://www.dietandcancerreport.org/
3. Parekh N, Okada T, Lu-Yao GL: Obesity, insulin resistance and cancer prognosis: Implications for practice for providing care among cancer survivors. J Am Diet Assoc 109:1346-1353, 2009
4. LeRoith D, Novasyadlyy R, Gallagher EJ, et al: Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis: Epidemiological and mechanistic evidence. Exp Clin Endocrinol Diabetes 116:S4-S6, 2008 (suppl 1)
5. Hedley A, Ogden C, Johnson C, et al: Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 291:2847-2850, 2004
6. James PT, Leach R, Kalamara E, et al: The worldwide obesity epidemic. Obes Res 9:228S-233S, 2001 (suppl 4)
7. Hursting SD, Lashinger LM, Wheatley KW, et al: Reducing the weight of cancer: Mechanistic targets for breaking the obesity-carcinogenesis link. Best Pract Res Clin Endocrinol Metab 22:659-669, 2008
8. Woods SC, Seeley RJ, Porte D Jr, et al: Signals that regulate food intake and energy homeostasis. Science 280:1378-1383, 1998 (Pubitemid 28264819)
9. Morris DI, Rui L: Recent advances in understanding leptin signaling and leptin resistance. Am J Physiol Endocrinol Metab 297:E1247-E1259, 2009
10. Stattin P, Lukanova A, Biessy C, et al: Obesity and colon cancer: Does leptin provide a link? Int J Cancer 109:149-152, 2004
11. Chang S, Hursting SD, Contois JH, et al: Leptin and prostate cancer. Prostate 46:62-67, 2001 (Pubitemid 32157777)
12. Wu MH, Chou YC, Chou WY, et al: Circulating levels of leptin, adiposity and breast cancer risk. Br J Cancer 100:578-582, 2009
13. Fenton JI, Hord NG, Lavigne JA, et al: Leptin, IGF-1 and IGF-2 are mitogens in murine models of preneoplastic, but not normal, colonic epithelial cells. Cancer Epidemiol Biomarkers Prev 14:1646-1652, 2005
14. Nikhata KJ, Ray A, Schuster TF, et al: Effects of adiponectin and leptin co-treatment on human breast cancer cell growth. Oncol Rep 21:1611-1619, 2009
15. Gonzalez RR, Cherfils S, Escobar M, et al: Leptin and its signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). J Biol Chem 281:26320-26328, 2006 (Pubitemid 44401840)
16. Cirillo D, Rachiglio AM, laMontagna R, et al: Leptin signaling in breast cancer: An overview. J Cell Biochem 105:956-964, 2008
17. min/+ colonic epithelial cell line. Carcinogenesis 27:1507-1515, 2006
18. Lim CT, Kola B, Korbonits M: AMPK as a mediator of hormonal signaling. J Mol Endocrinol 44:87-97, 2010
19. Barb D, Williams CJ, Neuwirth AK, et al: Adiponectin in relation to malignancies: A review of existing basic and clinical evidence. Am J Clin Nutr 86:s858-s866, 2007
20. Rzepka-Górska I, Bedner R, Cymbaluk-Płoska A, et al: Serum adiponectin in relation to endometrial cancer and endometrial hyperplasia with atypia in obese women. Eur J Gynaecol Oncol, 29:594-597, 2008
21. Tian YF, Chu CH, Wu MH, et al: Anthropometric measures, plasma adiponectin, and breast cancer risk. Endocr Relat Cancer 14:669-677, 2007
22. Wei EK, Giovannucci E, Fuchs CS, et al: Low plasma adiponectin levels and risk of colorectal cancer in men: A prospective study. J Natl Cancer Inst 97:1688-1694, 2005 (Pubitemid 41672235)
23. Sher DJ, Oh WK, Jacobus S, et al: Relationship between serum adiponectin and prostate cancer grade. Prostate 68:1592-1598, 2008
24. Bråkenhielm E, Veitonmä ki N, Cao R, et al: Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A 101:2476-2481, 2004 (Pubitemid 38269336)
25. Dai Q, Gao YT, Shu XO, et al: Oxidative stress, obesity, and breast cancer risk: Results from the Shanghai Women's Health Study. J Clin Oncol 27:2482-2488, 2009
26. Fenton JI, Birmingham J, Hursting SD, et al: Adiponectin blocks leptin-induced NFkβ DNA binding, interleukin-6 trans signaling and resulting cell proliferation in ApcMin colon epithelial cells. Int J Cancer 122:2437-2441, 2008
27. Kaaks R, Lukanova A, Kurzer MS: Obesity, endogenous hormones, and endometrial cancer risk: A synthetic review. Cancer Epidemiol Biomarkers Prev 11:1531-1543, 2002 (Pubitemid 36020003)
28. Birt DF, Przybyszewski J, Wang W, et al: Identification of molecular targets for dietary energy restriction prevention of skin carcinogenesis: An idea cultivated by Edward Bresnick. J Cell Biochem 91:258-264, 2004
29. Jiang W, Zhu Z, Bhatia N, et al: Mechanisms of energy restriction: Effects of corticosterone on cell growth, cell cycle machinery, and apoptosis. Cancer Res 62:5280-5287, 2002 (Pubitemid 35024603)
30. Pashko LL, Schwartz AG: Reversal of food restriction-induced inhibition of mouse skin tumor promotion by adrenalectomy. Carcinogenesis 13:1925-1928, 1992
31. Coussens LM, Werb Z: Inflammation and cancer. Nature 420:860-867, 2002 (Pubitemid 36019639)
32. Ceciliani F, Giordano A, Spagnolo V: The systemic reaction during inflammation: The acute-phase proteins. Protein Pept Lett 9:211-223, 2002 (Pubitemid 34580698)
33. Mantovani A, Sozzani S, Locati M, et al: Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23:549-555, 2002 (Pubitemid 35223554)
34. Sica A, Larghi P, Mancino A, et al: Macrophage polarization in tumour progression. Semin Cancer Biol 18:349-355, 2008
35. Lumeng CN, Deyoung SM, Bodzin JL, et al: Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 56:16-23, 2007
36. Furukawa S, Fujita T, Shimabukuro M, et al: Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Inv 114:1752-1761, 2004 (Pubitemid 40385531)
37. Valko M, Izakovic M, Mazur M, et al: Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem 266:37-56, 2004 (Pubitemid 39562306)
38. Dean RT, Fu S, Stocker R, et al: Biochemistry and pathology of radical-mediated protein oxidation. Biochem J 324:1-18, 1997 (Pubitemid 27229359)
39. Leslie NR: The redox regulation of PI 3-kinase-dependent signaling. Antioxid Redox Signal 8:1765-1774, 2006
40. Loft S, Poulsen HE: Cancer risk and oxidative DNA damage in man. J Mol Med, 75:67-68, 1996
41. Cooke MS, Evans MD, Dizdaroglu M, et al: Oxidative DNA damage: Mechanisms, mutation, and disease. FASEB J 10:1195-1214, 2003 (Pubitemid 36775767)
42. Ma J, Giovannucci E, Pollak M, et al: A prospective study of Plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst 96:546-553, 2004 (Pubitemid 38559579)
43. Michaud DS, Wolpin B, Giovannucci E, et al: Prediagnostic plasma C-peptide and pancreatic cancer risk in men and women. Cancer Epidemiol Biomarkers Prev 16:2101-2109, 2007 (Pubitemid 47621187)
44. Schairer C, Hill D, Sturgeon SR, et al: Serum concentrations of IGF-I, IGFBP-3 and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women. Int J Cancer 187:773-779, 2004 (Pubitemid 38076411)
45. Lukanova A, Zeleniuch-Jacquotte A, Lundin E, et al: Prediagnostic levels of C-peptide, IGF-I, IGFBP -1, -2 and -3 and risk of endometrial cancer. Int J Cancer 108:262-268, 2004 (Pubitemid 37541781)
46. Pollak M: Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915-928, 2008
47. Renehan AG, Frystyk J, Flyvbjerg A: Obesity and cancer risk: The role of the insulin-IGF axis. Trends Endocrinol Metab 17:328-336, 2006 (Pubitemid 44397568)
48. Calle EE, Kaaks R: Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4:579-591, 2004 (Pubitemid 39025053)
49. Hursting SD, Lavigne JA, Berrigan D, et al: Calorie restriction, aging, and cancer prevention: Mechanisms of action and applicability to humans. Annu Rev Med 54:131-152, 2003 (Pubitemid 37386388)
50. Hankinson SE, Willett WC, Colditz GA, et al: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:1393-1396, 1998 (Pubitemid 28209997)
51. Chan JM, Stampfer MJ, Giovannucci E, et al: Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 279:563-566, 1998 (Pubitemid 28067285)
52. Wolk A, Mantzoros CS, Andersson SO, et al: Insulin-like growth factor 1 and prostate cancer risk: A population-based, case-control study. J Natl Cancer Inst 90:911-915, 1998 (Pubitemid 28304159)
53. Yu H, Spitz MR, Mistry J, et al: Plasma levels of insulin-like growth factor-I and lung cancer risk: A case-control analysis. J Natl Cancer Inst 91:151-156, 1999 (Pubitemid 29042692)
54. Ma J, Pollak MN, Giovannucci E, et al: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91:620-625, 1999 (Pubitemid 29194048)
55. Giovannucci E, Pollak MN, Platz EA, et al: A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 9:345-349, 2000 (Pubitemid 30265776)
56. Petridou E, Dessypris N, Spanos E, et al: Insulin-like growth factor-I and binding protein-3 in relation to childhood leukaemia. Int J Cancer 80:494-496, 1999 (Pubitemid 29047510)
57. Hursting SD, Switzer BR, French JE, et al: The growth hormone: Insulin-like growth factor 1 axis is a mediator of diet restriction-induced inhibition of mononuclear cell leukemia in Fischer rats. Cancer Res 53:2750-2757, 1993
58. Dunn SE, Kari FW, French J, et al: Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res 57:4667-4672, 1997 (Pubitemid 27468963)
59. Moore T, Beltran L, Carbajal S, et al: Dietary energy balance modulates signaling through the Akt/Mammalian Target of Rapamycin pathways in multiple epithelial tissues. Cancer Prev Res 1:65-76, 2008
60. Nunez NP, Perkins SN, Smith NCP, et al: Obesity accelerates mouse mammary tumor growth in the absence of ovarian hormones. Nutr Cancer 60:534-541, 2008 (Pubitemid 351918549)
61. Takahashi K, Suzuki K: Association of insulin-like growth-factor-I- induced DNA synthesis with phosphorylation and nuclear exclusion of p53 in human breast cancer MCF-7 cells. Int J Cancer 55:453-458, 1993 (Pubitemid 23300598)
62. Allen NE, Roddam AW, Allen DS, et al: A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk. Br J Cancer 92:1283-1287, 2005 (Pubitemid 40604405)
63. Moore T, Carbijal S, Beltran L, et al: Reduced susceptibility to two-stage skin carcinogenesis in mice with low circulating IGF-1 levels. Cancer Res 68:3680-3688, 2008
64. Olivo-Marston S, Hursting SD, Lavigne J, et al: Genetic reduction of insulin-like growth factor-1 inhibits azoxymethane-induced colon tumorigenesis in mice. Mol Carcinog 48:1071-1076, 2009
65. Colman RJ, Anderson RM, Johnson SC, et al: Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 325:201-204, 2009
66. Kagawa Y: Impact of Westernization on the nutrition of Japanese: Changes in physique, cancer, longevity and centenarians. Prev Med 7:205-217, 1978
67. Yuan TL, Cantley LC: PI3K pathway alterations in cancer: Variations on a theme. Oncogene 27:5497-5510, 2008
68. Engelman JA: Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat Rev Cancer 9:550-562, 2009
69. Franke TF: PI3K/Akt: Getting it right matters. Oncogene 27:6473-6488, 2008
70. Brazil DP, Yang ZZ, Hemmings BA: Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochm Sci 29:233-242, 2004 (Pubitemid 38591317)
71. Guertin DA, Sabatini DM: An expanding role for mTOR in cancer. Trends Mol Med 11:353-361, 2005 (Pubitemid 41080576)
72. Shaw RJ, Bardeesy N, Manning BD, et al: The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6:91-99, 2004 (Pubitemid 38903165)
73. Corradetti MN, Inoki K, Badeesy N, et al: Regulation of the TSC pathway by LKB1: Evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev 18:1533-1538, 2004 (Pubitemid 38868905)
74. Shaw RJ, Kosmatka M, Bardeesy N, et al: The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A 101:3329-3335, 2004 (Pubitemid 38338195)
75. Astrinidis A, Henske EP: Tuberous sclerosis complex: Linking growth and energy signaling pathways with human disease. Oncogene 24:7475-7481, 2005 (Pubitemid 41637987)
76. Inoki K, Corradetti MN, Guan KL: Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37:19-24, 2005 (Pubitemid 40070934)
77. Tee AR, Blenis J: MTOR, translational control and human disease. Semin Cell Dev Biol 16:29-37, 2005 (Pubitemid 40126874)
78. Woods SC, Seeley RJ, Porte D Jr, et al: Signals that regulate food intake and energy homeostasis Science 280:1378-1383, 1998
79. Dann SG, Selvaraj A, Thomas G: mTOR Complex1-S6K1 signaling: At the crossroads of obesity, diabetes and cancer. Trends Mol Med 13:252-259
80. Jiang W, Zhu Z, Thompson HJ: Dietary energy restriction modulates the activity of Akt and mTOR in mammary carcinomas, mammary gland, and liver. Cancer Res 68:5492-5499, 2008
81. Jiang B, Liu L: Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatment. Drug Resist Updat 11:63-76, 2009
82. Loi S, Milne R, Friedlander M, et al: Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 14:1686-1691, 2005 (Pubitemid 40995080)
83. Bastarrachea J, Hortobagyi GN, Smith TL, et al: Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. Ann Intern Med 120:18-25, 1994 (Pubitemid 24011496)
84. Kalaany NY, Sabatini DM: Tumours with PI3K activation are resistant to dietary restriction. Nature 458:725-731, 2009
85. Anastasiou D, Krek W: SIRT1: Linking adaptive cellular responses to aging-associated changes in organismal physiology. Physiology (Bethesda) 21:404-410, 2006 (Pubitemid 44879249)
86. Yang T, Fu M, Pestell R, et al: SIRT1 and endocrine signaling. Trends Endocrinol Metab 17:186-191, 2006 (Pubitemid 43974972)
87. Cohen HY, Miller C, Bitterman KJ, et al: Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 305:390-392, 2004 (Pubitemid 38938153)
88. Metoyer CF, Pruitt K: The role of sirtuin proteins in obesity. Pathophysiology 15:103-108, 2008
89. Lin SJ, Defossez PA, Guarente L: Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science 289:2126-2128, 2000
90. Anderson RM, Bitterman KJ, Wood JG, et al: Nicotinamide and PNC1 govern lifespan extension by calorie restriction in Saccharomyces cerevisiae. Nature 423:181-185, 2003 (Pubitemid 36569542)
91. Tissenbaum HA, Guarente L: Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 410:227-230, 2001 (Pubitemid 32216597)
92. Picard F, Kurtev M, Chung N, et al: Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429:771-776, 2004 (Pubitemid 38833129)
93. Qiang L, Wang H, Farmer SR: Adiponectin secretion is regulated by SIRT1 and the endoplasmic reticulum oxidoreductase Ero1-L alpha. Mol Cell Biol 27:4698-4707, 2007 (Pubitemid 47016124)
94. Qiao L, Shao J: SIRT1 regulates adiponectin gene expression through Foxo1-C/enhancer-binding protein alpha transcriptional complex. J Biol Chem 281:39915-39924, 2006 (Pubitemid 46041795)
95. Bordone L, Cohen D, Robinson A, et al: SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell 6:759-767, 2007 (Pubitemid 350131044)
96. Ramsey KM, Mills KF, Satoh A, et al: Age-associated loss of Sirt1-mediated enhancement of glucose-stimulated insulin secretion in beta cell-specific Sirt1-overexpressing (BESTO) mice. Aging Cell 7:78-88, 2008
97. Nemoto S, Fergusson MM, Finkel T: SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha}. J Biol Chem 280:16456-16460, 2005 (Pubitemid 40616776)
98. Nisoli E, Tonello C, Cardile A, et al: Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science 310:314-317, 2005 (Pubitemid 41457197)
99. Yechoor VK, Patti ME, Ueki K, et al: Distinct pathways of insulin-regulated versus diabetes-regulated gene expression: An in vivo analysis in MIRKO mice. Proc Natl Acad Sci U S A 101:16525-16530, 2004 (Pubitemid 39557746)
100. Lim CS: SIRT1: Tumor promoter or tumor suppressor? Med Hypotheses 67:341-344, 2006
101. Ford J, Jiang M, Milner J: Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res 65:10457-10463, 2005 (Pubitemid 41743740)
102. Chen WY, Wang DH, Yen RC, et al: Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 123:437-448, 2005 (Pubitemid 41546674)
103. Huffman DM, Grizzle WE, Bamman MM, et al: SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 67:6612-6618, 2007 (Pubitemid 47105506)
104. Kim JE, Chen J, Lou Z: DBC1 is a negative regulator of SIRT1. Nature 451:583-586, 2008 (Pubitemid 351186264)
105. Zhao W, Kruse JP, Tang Y, et al: Negative regulation of the deacetylase SIRT1 by DBC1. Nature 451:587-590, 2008 (Pubitemid 351186268)
106. Firestein R, Blander G, Michan S, et al: The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS ONE 3:e2020, 2008
107. Baur JA, Sinclair DA: Therapeutic potential of resveratrol: The in vivo evidence. Nat Rev Drug Discov 5:493-506, 2006 (Pubitemid 44136961)
108. Alberti KG, Eckel RH, Grundy SM, et al: Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640-1645, 2009
109. Cowey S, Hardy RW: The metabolic syndrome: A high-risk state for cancer? Am J Pathol 169:1505-1522, 2006
110. Giovannucci E: Metabolic syndrome, hyperinsulinemia, and colon cancer: A review. Am J Clin Nutr 86:s836-s842, 2007
111. Xue F, Michels KB: Diabetes, metabolic syndrome, and breast cancer: A review of the current evidence. Am J Clin Nutr 86:s823-s835, 2007
112. Pothiwala P, Jain SK, Yaturu S: Metabolic syndrome and cancer. Metab Synd Relat Disord 7:279-288, 2009
113. le Roux CW, Aylwin SJ, Batterham RL, et al: Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 243:108-114, 2006 (Pubitemid 43054062)
114. Sjö ström L, Gummesson A, Sjö ström CD, et al: Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): A prospective, controlled intervention trial. Lancet Oncol 10:653-662, 2009
115. Carpenter C, Ross PK, Paganini-Hill A, et al: Effect of family history, obesity, and exercise on breast cancer risk among post-menopausal women. Int J Cancer 106:96-102, 2003 (Pubitemid 36750394)
116. Mai PL, Sullivan-Halley J, Ursin G, et al: Physical activity and colon cancer risk among women in the California Teachers Study. Cancer Epidemiol Biomarkers Prev 16:517-525, 2007 (Pubitemid 46548655)
117. Rogers CJ, Colbert LH, Greiner JW, et al: Physical activity and cancer prevention: Pathways and targets for intervention. Sports Med 38:271-296, 2008 (Pubitemid 351430296)
118. Moore SC, Rajaraman P, Dubrow R, et al: Height, body mass index, and physical activity in relation to glioma risk. Cancer Res 69:8349-8355, 2009
119. Nock NL, Thompson CL, Berger NA, et al: Association between obesity and changes in adult BMI over time and colon cancer risk. Obesity 16:1099-1104, 2008 (Pubitemid 351620484)
120. Donehower LA, French JE, Hursting SD: The utility of genetically altered mouse models for cancer research. Mutat Res 576:1-3, 2005 (Pubitemid 40982678)
121. Hursting SD, Nunez NP, Varticovski L, et al: The obesity-cancer link: Lessons learned from a fatless mouse. Cancer Res 67:2391-2393, 2007 (Pubitemid 46548919)
122. Wu Y, Yakar S, Zhao L, et al: Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res 62:1030-1035, 2002 (Pubitemid 34160283)
123. Friedman JM, Halaas JL: Leptin and the regulation of body weight in mammals. Nature 395:763-770, 1998 (Pubitemid 28485436)
124. Hakimi P, Yang J, Casadesus G, et al: Overexpression of the cytosolic form of phosphoenolpyruvate carboxykinase (GTP) in skeletal muscle repatterns energy metabolism in the mouse. J Biol Chem 282:32844-32855, 2007 (Pubitemid 350159290)
125. Cho RW, Clarke MF: Recent advances in cancer stem cells. Curr Opin Genet Dev 18:48-53, 2008 (Pubitemid 351694448)
126. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100:3983-3988, 2003 (Pubitemid 36418143)
127. Charafe-Jauffret E, Monville F, Ginestier C, et al: Cancer stem cells in breast: Current opinion and future challenges. Pathobiology 75:75-84, 2008 (Pubitemid 351820725)
128. Dave B, Chang J: Treatment resistance in stem cells and breast cancer. J Mammary Gland Biol Neoplasia 14:79-82, 2009
129. Richmond A, Su Y: Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech 1:78-82, 2008
130. Ciardiello F, Tortora G: EGFR antagonists in cancer treatment. N Engl J Med 358:1160-74, 2008
131. Spector NL, Blackwell KL: Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 27:5838-5847, 2009
132. Motzer RJ, Escudier B, Oudard S, et al: Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449-456, 2008
133. Hess G, Herbrecht R, Romaguera J, et al: Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle-cell lymphoma. J Clin Oncol 27:3822-3829, 2009
134. Sachdev D, Yee D: Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 6:1-12, 2007 (Pubitemid 46206663)
135. Goodwin PJ, Ligibel JA, Stambolic V: Metformin in breast cancer: Time for action. J Clin Oncol 27:3271-3273, 2009
136. Zakikhani M, Dowling R, Fantus IG, et al: Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66:10269-10273, 2006 (Pubitemid 44799743)
137. Jiralerspong S, Palla SL, Giordano SH, et al: Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27:3297-3302, 2009
138. Markowitz SD: Aspirin and colon cancer: Targeting prevention? N Engl J Med 356:2195-2198, 2007
139. Bresalier RS, Sandler RS, Quan H, et al: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092-1002, 2005
140. Solomon SD, McMurray JJ, Pfeffer MA, et al: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071-80, 2005 (Pubitemid 40365348)